WallStSmart

Fold Holdings, Inc. Class A Common Stock (FLD)vsNomura Holdings Inc ADR (NMR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Nomura Holdings Inc ADR generates 8262710% more annual revenue ($2.33T vs $28.21M). NMR leads profitability with a 17.3% profit margin vs -258.6%. NMR earns a higher WallStSmart Score of 84/100 (A-).

FLD

Hold

38

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 2/9Altman Z: -2.33

NMR

Exceptional Buy

84

out of 100

Grade: A-

Growth: 10.0Profit: 7.0Value: 7.0Quality: 3.0
Piotroski: 4/9Altman Z: 0.53

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FLD2 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

EPS GrowthGrowth
1622.0%10/10

Earnings expanding 1622.0% YoY

NMR6 strengths · Avg: 9.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Operating MarginProfitability
30.8%10/10

Strong operational efficiency at 30.8%

Revenue GrowthGrowth
31.2%10/10

Revenue surging 31.2% year-over-year

PEG RatioValuation
0.828/10

Growing faster than its price suggests

P/E RatioValuation
12.8x8/10

Attractively priced relative to earnings

EPS GrowthGrowth
42.0%8/10

Earnings expanding 42.0% YoY

Areas to Watch

FLD4 concerns · Avg: 2.5/10
Market CapQuality
$25.46M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-137.2%2/10

ROE of -137.2% — below average capital efficiency

Revenue GrowthGrowth
-25.5%2/10

Revenue declined 25.5%

NMR2 concerns · Avg: 1.5/10
Altman Z-ScoreHealth
0.532/10

Distress zone — elevated risk

Debt/EquityHealth
9.181/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : FLD

The strongest argument for FLD centers on Price/Book, EPS Growth.

Bull Case : NMR

The strongest argument for NMR centers on Price/Book, Operating Margin, Revenue Growth. Profitability is solid with margins at 17.3% and operating margin at 30.8%. Revenue growth of 31.2% demonstrates continued momentum.

Bear Case : FLD

The primary concerns for FLD are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : NMR

The primary concerns for NMR are Altman Z-Score, Debt/Equity. Debt-to-equity of 9.18 is elevated, increasing financial risk.

Key Dynamics to Monitor

FLD profiles as a turnaround stock while NMR is a growth play — different risk/reward profiles.

NMR carries more volatility with a beta of 0.61 — expect wider price swings.

NMR is growing revenue faster at 31.2% — sustainability is the question.

Monitor CAPITAL MARKETS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NMR scores higher overall (84/100 vs 38/100), backed by strong 17.3% margins and 31.2% revenue growth. Both earn "Exceptional Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fold Holdings, Inc. Class A Common Stock

FINANCIAL SERVICES · CAPITAL MARKETS · USA

Fold Holdings, Inc. (FLD) is an innovative biotechnology firm dedicated to the development of groundbreaking therapies for severe genetic and rare diseases, utilizing advanced research methodologies and proprietary technologies. With a promising product pipeline bolstered by strategic collaborations, the company is poised to capitalize on substantial market opportunities within the healthcare sector. Fold's steadfast focus on scientific excellence and patient-centered solutions underscores its potential as a significant investment prospect, offering the promise of long-term growth and enhanced shareholder value in an evolving industry landscape.

Visit Website →

Nomura Holdings Inc ADR

FINANCIAL SERVICES · CAPITAL MARKETS · USA

Nomura Holdings, Inc. provides various financial services to individuals, corporations, financial institutions, governments, and government agencies worldwide. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?